EUVIMEDEUVIMED entdecken
Crossref

Cyclosporine Attenuates Covid-19: Ensnare or Victory

Hayder M. Al-kuraishy, Ali I Al-Gareeb, Safaa Qusti, Ifeoma C. Orabueze, Naeem Quasty, Eida M. Alshammari, El-Saber Batiha GE

Annals of Clinical and Medical Case Reports · 2021

DOI: 10.47829/acmcr.2021.7402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Medical Case Reports, 2021. Verfasst von Hayder M. Al-kuraishy und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

. Abstract Coronavirus disease 2019 (Covid-19) is a recent worldwide pandemic caused by a novel severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2). In critical cases it causes acute lung injury (ALI) due to severe acute respiratory distress syndrome (ARDS). It has been proposed that initial immunological activation in SARS-CoV-2 infection is necessary for elimination and clearance of viral infection; however exaggerated late immune response is associated with immunological-mediated tissue injury. Thus, regulation of immune response by immunosuppressive agents may prevent exaggerated immune response-mediated development of ALI and/ or ARDS. Cyclosporine A (CsA) is an immunosuppressive drug that has been suggested by different studies to be effective against Covid-19 owing to potential antiviral and anti-inflammatory prop - erties. In this case study, we report cases of five Covid-19 patients with psoriasis, rheumatoid arthritis and ulcerative colitis on CsA therapy compared with five control Covid-19 patients not placed on CsA therapy. CsA therapy was given concurrently with the standard treatments in Covid-19 patients that received the therapy. The objective of the present study was to evaluate the outcome of including CsA therapy in management of Covid-19. The primary outcome parameters were hospital discharge time and mortality, while the secondary outcomes were clinical score severity and radiological resolution. CsA therapy in the reported cases led to significant attenuation of Covid-19 severity as revealed through good primary outcomes of short hospitalization period and no mortality compared with control Covid-19 patients. The secondary outcomes of Covid-19 patients on CsA therapy showed a significantly improved clinical signs. The biomarkers used for clinical score severity, CT scan scores, oxygen saturations, inflammation evalu - ation suggested better outcome compared to control Covid-19 patients. In conclusion, preexistent CsA therapy attenuates Covid-19 severity and mortality with significant reduction of inflammatory state. Therefore, CsA may reduce Covid-19 severity through anti-inflammatory and anti-SARS-CoV-2

Zitieren

APA

Al-kuraishy, H. M., Al-Gareeb, A. I., Qusti, S., Orabueze, I. C., Quasty, N., Alshammari, E. M., & GE, E. B. (2021). Cyclosporine Attenuates Covid-19: Ensnare or Victory. Annals of Clinical and Medical Case Reports. https://doi.org/10.47829/acmcr.2021.7402

Vancouver

Al-kuraishy HM, Al-Gareeb AI, Qusti S, Orabueze IC, Quasty N, Alshammari EM, et al. Cyclosporine Attenuates Covid-19: Ensnare or Victory. Annals of Clinical and Medical Case Reports. 2021. doi:10.47829/acmcr.2021.7402

BibTeX
@article{Alkuraishy2021,
  author = {Al-kuraishy, Hayder M. and Al-Gareeb, Ali I and Qusti, Safaa and Orabueze, Ifeoma C. and Quasty, Naeem and Alshammari, Eida M. and GE, El-Saber Batiha},
  title = {Cyclosporine Attenuates Covid-19: Ensnare or Victory},
  journal = {Annals of Clinical and Medical Case Reports},
  year = {2021},
  doi = {10.47829/acmcr.2021.7402}
}
Kostenlos starten →